Clinical trials: Contraceptives, Oral
- Condition Contraceptives, Oral
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Contraception
Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System
The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.
- Trial name
- NCT01181479
- Testing
- AG200-15 (cycles 1-13), Lessina crossover to AG200-15
- Where
- 80 sites in United States
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- Agile Therapeutics
Acne Vulgaris
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles.
- Trial name
- NCT00651469
- Testing
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
- Where
- 27 sites in United States
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bayer
Safety
Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants between the age of 12 and 17 years + 2 months.
- Trial name
- NCT04792385
- Testing
- E4/DRSP 15/3 mg combined tablet
- Where
- 23 sites in Estonia, Finland and 4 more
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Estetra
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bone Mineral Density
A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females
This study is being conducted to compare the effects of a 91-day oral contraceptive (OC) to a 28-day OC regimen on bone mineral density (BMD) in adolescent females.
- Trial name
- NCT00924560
- Testing
- 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive
- Where
- 46 sites in United States
- Volunteers
- 1,361 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Contraception
A Study of Oral Contraception Under Simulated OTC Conditions
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
- Trial name
- OPTION (NCT03559010)
- Testing
- Norgestrel 0.075 mg tablets
- Where
- 44 sites in United States
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acne Vulgaris
GA YAZ ACNE in China Phase III
The purpose of this study is to evaluate the efficacy and safety of YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) in comparison with placebo in female patients with moderate acne vulgaris over 6 treatment cycles.
- Trial name
- NCT00818519
- Testing
- EE20/Drospirenone (YAZ, BAY86-5300)
- Where
- 7 sites in China
- Volunteers
- 179 people
- Sponsor
- Bayer
Dysmenorrhea
A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval.
- Trial name
- NCT00196313
- Testing
- levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Duramed Research
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
The purpose of the study is to investigate if NNC0519-0130 affects the blood levels of a birth control pill that contains the two hormones ethinylestradiol and levonorgestrel.
- Trial name
- NCT06513104
- Testing
- NNC0519-0130, Levonorgestrel + Ethinylestradiol, Paracetamol
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Novo Nordisk A/S
Contraception
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
- Trial name
- NCT02269241
- Testing
- LF111 (drospirenone)
- Where
- 37 sites in United States
- Volunteers
- 1,552 people, healthy volunteers welcome
- Sponsor
- Laboratories Leon Farma, S.A.
Contraception
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
- Trial name
- ACCESS (NCT04112095)
- Testing
- Norgestrel 0.075 mg tablets
- Where
- 38 sites in United States
- Volunteers
- 962 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Contraception, Female Contraception
A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control
The purpose of the study is to use data from a health care information database to assess the risk of venous thromboembolism (blood clots), myocardial infarction (heart attacks), and stroke among women using a transdermal…
- Trial name
- NCT00377988
- Testing
- Transdermal Contraceptive System, Norgestimate-containing oral contraceptives with EE
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study
The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in…
- Trial name
- NCT02817841
- Testing
- 15 mg E4/3 mg DRSP
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,148 people, healthy volunteers welcome
- Sponsor
- Estetra
Acne Vulgaris
Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles
- Trial name
- NCT00656981
- Testing
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
- Where
- 22 sites in United States
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Bayer
Dysmenorrhea
Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea
The purpose of this study is to determine whether combination oral contraceptive pill of norethindrone and ethinyl estradiol is effective in the treatment of primary dysmenorrhea.
- Trial name
- NCT00746096
- Testing
- IKH-01
- Volunteers
- 115 people
- Sponsor
- Nobelpharma
Acne Vulgaris
Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa
The purpose of the study is to determine safety and efficacy of an oral contraceptive in treating acne papulopustulosa.
- Trial name
- NCT00280657
- Testing
- Valette, Diane
- Where
- 62 sites in Czechia, Poland and 3 more
- Volunteers
- 1,326 people
- Sponsor
- Bayer
Contraception, Change in Bone Mineral Density
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113.
- Trial name
- NCT05461573
- Testing
- Drospirenone
- Where
- 47 sites in United States, Canada
- Volunteers
- 1,542 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Contraceptives, Oral, Combined
Observational Trial With Leios/Alesse
A prospective, observational study (Anwendungsbeobachtung [AWB]) of the prescribing and administration practices of German gynecologists with Leios® Dragées.
- Trial name
- NCT00481650
- Testing
- Leios/Alesse
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Contraception
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
- Trial name
- NCT05264506
- Testing
- NOMAC-E2 COC
- Where
- 103 sites in United States
- Volunteers
- 3,055 people
- Sponsor
- Organon and Co